The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

Cancer Biology and Therapy

Volumn 13, Issue 11, 2012, Pages 1072-1081

  Prevo, Remko ^a   Fokas, Emmanouil ^a   Reaper, Philip M ^b   Charlton, Peter A ^b   Pollard, John R ^b   McKenna, W Gillies ^a   Muschel, Ruth J ^a   Brunner, Thomas B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

ATR; Chemotherapy; Hypoxia; Inhibitor; Radiosensitivity

Indexed keywords

CHECKPOINT KINASE 1; GAMMA H2AX PROTEIN; GEMCITABINE; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAD51 PROTEIN; UNCLASSIFIED DRUG; VE 821;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SENSITIZATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PROTEIN PHOSPHORYLATION; RADIOSENSITIZATION; RECOMBINATION REPAIR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL HYPOXIA; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DNA DAMAGE; DNA REPAIR; HUMANS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PYRAZINES; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; SULFONES;

EID: 84865843265     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21093     Document Type: Article

References (38)

1. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009; 6:699-708; PMID:19806144; http://dx.doi.org/10.1038/nrgastro.2009.177.
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362:1605-17; PMID:20427809; http://dx.doi.org/10.1056/NEJMra0901557.
3. Brunner TB, Scott-Brown M. The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol 2010; 5:64; PMID:20615227; http://dx.doi.org/10.1186/1748-717X-5-64.
4. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22:1430-8; PMID:15084616; http://dx.doi.org/10.1200/JCO.2004.10.112.
5. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA; Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19:3447-55; PMID:11481349.
6. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23:8033-40; PMID:16258101; http://dx.doi.org/10.1200/JCO.2005.01.9661.
7. Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, Okusaka T, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011; 12:256-62; PMID:21306953; http://dx.doi.org/10.1016/ S1470-2045(11)70004-3.
8. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, et al.; National Cancer Institute of Canada Clinical Trials Group. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:3296-302; PMID:12947065; http://dx.doi.org/10.1200/JCO.2003.02. 098.
9. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28:3605-10; PMID:20606093; http://dx.doi.org/10.1200/JCO.2009.25.7550.
10. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6; PMID:17452677; http://dx.doi.org/10. 1200/JCO.2006.07.9525.
11. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7:163-72; PMID:20101258; http://dx.doi.org/10.1038/nrclinonc.2009.236.
12. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011; 11:239-53; PMID:21430696; http://dx.doi.org/10.1038/nrc3007.
13. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8:193-204; PMID:18256616; http://dx.doi.org/10.1038/nrc2342.
14. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-6; PMID:18772397; http://dx.doi.org/10.1126/ science.1164368.
15. Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, et al. Single nucleotide polymorphisms of RecQ1, RAD54L and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 2006; 24:1720-8; PMID:16520463; http://dx.doi.org/10.1200/JCO.2005.04.4206.
16. Okazaki T, Jiao L, Chang P, Evans DB, Abbruzzese JL, Li D. Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin Cancer Res 2008; 14:2042-8; PMID:18381943; http://dx.doi.org/10.1158/1078-0432.CCR-07-1520.
17. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461:1071-8; PMID:19847258; http://dx.doi.org/10.1038/ nature08467.
18. López-Contreras AJ, Fernandez-Capetillo O. The ATR barrier to replication-born DNA damage. DNA Repair (Amst) 2010; 9:1249-55; PMID:21036674; http://dx.doi.org/10.1016/j.dnarep.2010.09.012.
19. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011; 7:428-30; PMID:21490603; http://dx.doi.org/10.1038/nchembio.573.
20. Ruzankina Y, Schoppy DW, Asare A, Clark CE, Vonderheide RH, Brown EJ. Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nat Genet 2009; 41:1144-9; PMID:19718024; http://dx.doi.org/10.1038/ng.441.
21. Tao Y, Leteur C, Yang C, Zhang P, Castedo M, Pierré A, et al. Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 2009; 8:1196-205; PMID:19305158; http://dx.doi.org/10.4161/cc.8.8.8203.
22. Toledo LI, Murga M, Fernandez-Capetillo O. Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol 2011; 5:368-73; PMID:21820372; http://dx.doi.org/10.1016/j.molonc.2011.07.002.
23. Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000; 48:919-22; PMID:11072146; http://dx.doi.org/10.1016/S0360-3016(00)00803-8.
24. Onozuka H, Tsuchihara K, Esumi H. Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs. Cancer Sci 2011; 102:975-82; PMID:21255190; http://dx.doi.org/10.1111/j.1349-7006.2011.01880.x.
25. Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004; 10:2299-306; PMID:15073105; http://dx.doi.org/10.1158/1078-0432.CCR-03-0488.
26. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25:326-31; PMID:17235048; http://dx.doi.org/10.1200/JCO.2006.07. 5663.
27. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006; 5:787-96; PMID:16648548; http://dx.doi.org/10.1158/1535-7163. MCT-06-0005.
28. Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res 2010; 70:9693-702; PMID:21098704; http://dx.doi.org/10.1158/ 0008-5472.CAN-10-2286.
29. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002; 62:2890-6; PMID:12019169.
30. López-Contreras AJ, Fernandez-Capetillo O. The ATR barrier to replication-born DNA damage. DNA Repair (Amst) 2010; 9:1249-55; PMID:21036674; http://dx.doi.org/10.1016/j.dnarep.2010.09.012.
31. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montaña MF, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 2011; 18:1331-5; PMID:22120667; http://dx.doi.org/10.1038/nsmb.2189.
32. Schoppy DW, Ragland RL, Gilad O, Shastri N, Peters AA, Murga M, et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin Invest 2012; 122:241-52; PMID:22133876; http://dx.doi.org/10.1172/JCI58928.
33. Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S, et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol 2011; 18:721-7; PMID:21552262; http://dx.doi.org/10.1038/nsmb.2076.
34. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70:4972-81; PMID:20501833; http://dx.doi.org/10.1158/ 0008-5472.CAN-09-3573.
35. Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 2011; 105:372-81; PMID:21730979; http://dx.doi.org/10.1038/bjc.2011.243.
36. Wagner JM, Kaufmann SH. Prospects for the Use of ATR Inhibitors to Treat Cancer. Pharmaceuticals (Ott) 2010; 3:1311-34; http://dx.doi.org/10.3390/ ph3051311.
37. Martin NE, Brunner TB, Kiel KD, DeLaney TF, Regine WF, Mohiuddin M, et al. A phase I trial of the dual farnesyltransferase and geranylgeranyl- transferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res 2004; 10:5447-54; PMID:15328183; http://dx.doi.org/10. 1158/1078-0432.CCR-04-0248.
38. Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008; 68:5915-23; PMID:18632646; http://dx.doi.org/10.1158/0008-5472.CAN-08-0757.